Sam Llewellyn, MPH

Associate Director, Patient Centered Research

Sam is an Associate Director of Patient Centered Research at Vitaccess.
He provides direction and oversight to a range of projects across our health economics and outcomes research, patient-centered outcomes, and real-world evidence portfolio. This includes our CMT&Me study, a first-of-its-kind observational registry collecting real-world data from over 3,500 people living with Charcot-Marie-Tooth disease across the US and Europe. Sam’s leadership of the project has ensured its success for both our client and the patient participants: the study has not only been approved for a three-year extension, but it also boasts an impressive participant recruitment and retention rate.
Sam’s day-to-day responsibilities include study design and implementation, ethical approval strategy and submissions, conduct and analysis of Delphi panels and qualitative interviews, and publication development.
Sam joined Vitaccess in 2018, after spending three years as a project manager within the PCO group at a leading contract research organization, where he managed large, multi-country outcomes research studies.
Sam has worked across a broad range of therapeutic areas, including gastrointestinal, oncology, respiratory, and rare neurodegenerative diseases. He has a particular interest in rare diseases.
His work has been presented at numerous national and international conferences, and published in peer-reviewed journals including Neurodegenerative Disease Management and Patient Preference and Adherence.
Sam holds a Bachelor’s degree in Psychology from Swansea University and a Master’s in Public Health from Oxford Brookes University.
In his spare time, he trains for triathlons, completing his biggest challenge to date – Ironman Barcelona – in October 2017.
Areas of expertise
Delphi panels
Cross-sectional surveys
Patient preference studies
Health-state utility studies
Adherence studies
Sam has co-authored many of our publications. The full library can be found on our publications page.
Skip to content